Amakem's rock inhibitor rolling towards the market
This article was originally published in Scrip
Executive Summary
Belgian biotech company Amakem has begun a proof-of-concept study with its lead product, the rho kinase (ROCK) inhibitor AMA0076, in glaucoma and ocular hypertension, after raising €18 million last year in a series A financing. The product is designed to avoid the risk of systemic and local side-effects such as hyperaemia that have caused problems for other products in this class, and uses the company's Localized Drug Action platform.